Many people around the world suffer from liver diseases and are becoming a serious concern globally owing to the rise in geriatric population and the increasing obesity rates. Liver diseases mainly include cirrhosis, hepatitis B & C, and liver cancer. Recently, the Food and Drug Administration has given a 510(k) clearance to Philips to commercialize its ElastQ Imaging that offers a non-invasive evaluation of tissue stiffness to give inclusive solution for liver disease estimation, monitoring, and treatment.
ElastQ Imaging facilitates concurrent imaging of tissue and evaluation of its stiffness, which is necessary for the analysis of several liver conditions. Now, with the help of ElastQ, clinicians have an exclusive solution to evaluate and analyze liver disorders without the need for liver biopsy or the pain related to it. With the use of shear wave elastography to concentrate on determining the stiffness of soft tissue, ElastQ imaging is simpler, reproducible, and non-invasive.
The system provides the user:
- Larger field of view or region of interest;
- Instantaneous response and smart analysis;
- Color-coded quantitative estimation of tissue stiffness; and
- Quantitative evaluations with multiple sample points.
Additionally, the ultrasound liver solution by Philips also consists of a set of characteristics, which makes it a potent device for clinicians:
- PureWave transducer technology, providing superior quality of image and raised infiltration in patients that are critical to image technically;
- Image fusion & navigation with anatomical intelligence, rising the control of instantaneous ultrasound assessments via multimodality fusion & interventional guidance; and
- Contrast-enhanced ultrasound, offering assurance in liver lesion recognition and characterization.
The ultrasound liver solution by Philips integrates a usual ultrasound imaging assessment of the liver structure with the values of stiffness of targeted tissue, enabling the clinicians to gain a baseline evaluation avoiding the wait time linked with tissue biopsy. This non-invasive ultrasound evaluation can be more comfortable for patients in comparison to the traditional liver biopsy that demands the utilization of needles. The assessment outcomes from ultrasound are accessible immediately that, in turn, assists in decreasing the anxiety felt by patients while waiting for the end results.
We hope most of the patients will be benefited with this new device. What is your opinion about the same?